Our overall ambition is to develope neuroprotective and potentially neurorestorative treatment which is –as yet- unavailable.
With respect to anti-viral strategies, GeneCode designed and develops improved molecules using antisense mechanism of action which targets viral genomes and transcripts. Enterprise Estonia have confirmed their support for an Applied Research Program to develop a small molecule Glial cell line – Derived Neurotrophic Factor (GDNF) mimetics, for the treatment of Parkinson’s Disease and other indications.
GeneCode applies proprietary drug design technologies for innovative target mechanisms. This enables the synthesis and development of novel small-molecule drug candidates which validates the target biology towards its proposed indications, such as Parkinson`s disease, spinal cord injury, Huntington`s disease, motor neuronal disease, multiple sclerosis, Alzheimer`s disease and pain.
GeneCode designed and develops improved molecules using antisense mechanism of action which targets viral genomes and transcripts. By disrupting the viral lifecycle GeneCode`s approach is delivering promising treatment options for Hepatitis C, HIV and Chikungunya virus.
All proprietary methods for novel drug design technologies and drug candidates developed by GeneCode are aimed to function as disease modifyers and ultimately as cures, not as disease symptom treatments
Both the identification and optimization of small molecule methods towards growth factor receptors and the antisense technologies have been globally patented and serve GeneCode`s new Technological Platforms of drug design.
GENECODE scientific partners are all internationally well known leading scientists in various areas of biomedical sciencies. GENECODE scientific partners have published more then 600 publications with more then 30 000 citations and are inventors or coinventors of more than 50 patent families and patents.